Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Adult Acute Lymphoblastic Leukemia

The Specialized Working Group on Adult Acute Lymphoblastic Leukemia consists mainly of the members of the EWALL group, which is the European Working Group for Adult ALL. This includes the leaders of the national ALL study groups in Europe.

Read more

Registration

Register here

The registration fee for the ESH-EBMT-EHA-IPIG 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Read more

Highlights of Past EHA (HOPE) Latin America 2020

EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.

Read more

5th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 5th edition of the jointly organized European CAR T-cell Meeting.

Read more

ASCAT 2023

EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 18th Annual Sickle Cell & Thalassaemia Conference.

Read more